UNLABELLED: New well-characterized preclinical models of prostate cancer (CaP) bone metastases are needed to improve our understanding of the development of CaP-related bone disease in patients. Here we describe characterization of a model consisting of direct injection of C4-2 cells into tibias. INTRODUCTION: Prostate cancer (CaP) has a high proclivity to metastasize to bone. Development and characterization of preclinical models of CaP bone metastases are of high interest. The objective of this study was to characterize C4-2 bone metastases and their response to castration. MATERIALS AND METHODS: Cell suspensions of C4-2, a subline of LNCaP, were injected directly into the tibias of intact male mice. In groups A (n = 7) and B (n = 5), animals were killed 3 and 8 weeks after injection of C4-2 cells, respectively. In group C (n = 7), animals were castrated 3 weeks after injection and killed 5 weeks after castration. Serum prostate-specific antigen (PSA) levels and bone mineral density (BMD) were measured, and bone histomorphometric analysis was performed. RESULTS: C4-2 cells decreased BMD of the injected tibias by 36.1% and bone volume by 74.1% versus normal tibias. Castration caused a 32.3% drop in serum PSA (p = 0.0438), with a nadir at day 14, after which it began to rise again. Bone destruction in the tumorous tibias of castrated animals was decreased by 15.9% versus tumorous tibias of intact animals (p = 0.0392). However, BMD in the tumorous tibias of castrated mice was still lower than in normal tibias of intact animals. Castration also decreased BMD and bone volume in nontumorous tibias (p = 0.0406 and 0.0232, respectively). CONCLUSIONS: The C4-2 model of bone metastasis recapitulates the response to androgen deprivation observed in CaP patients with bone metastases and is suitable for study of interactions between tumor and bone cells and evaluation of new therapeutic modalities.
UNLABELLED: New well-characterized preclinical models of prostate cancer (CaP) bone metastases are needed to improve our understanding of the development of CaP-related bone disease in patients. Here we describe characterization of a model consisting of direct injection of C4-2 cells into tibias. INTRODUCTION:Prostate cancer (CaP) has a high proclivity to metastasize to bone. Development and characterization of preclinical models of CaP bone metastases are of high interest. The objective of this study was to characterize C4-2bone metastases and their response to castration. MATERIALS AND METHODS: Cell suspensions of C4-2, a subline of LNCaP, were injected directly into the tibias of intact male mice. In groups A (n = 7) and B (n = 5), animals were killed 3 and 8 weeks after injection of C4-2 cells, respectively. In group C (n = 7), animals were castrated 3 weeks after injection and killed 5 weeks after castration. Serum prostate-specific antigen (PSA) levels and bone mineral density (BMD) were measured, and bone histomorphometric analysis was performed. RESULTS:C4-2 cells decreased BMD of the injected tibias by 36.1% and bone volume by 74.1% versus normal tibias. Castration caused a 32.3% drop in serum PSA (p = 0.0438), with a nadir at day 14, after which it began to rise again. Bone destruction in the tumorous tibias of castrated animals was decreased by 15.9% versus tumorous tibias of intact animals (p = 0.0392). However, BMD in the tumorous tibias of castrated mice was still lower than in normal tibias of intact animals. Castration also decreased BMD and bone volume in nontumorous tibias (p = 0.0406 and 0.0232, respectively). CONCLUSIONS: The C4-2 model of bone metastasis recapitulates the response to androgen deprivation observed in CaPpatients with bone metastases and is suitable for study of interactions between tumor and bone cells and evaluation of new therapeutic modalities.
Authors: Hung-Ming Lam; Ryan McMullin; Holly M Nguyen; Ilsa Coleman; Michael Gormley; Roman Gulati; Lisha G Brown; Sarah K Holt; Weimin Li; Deborah S Ricci; Karin Verstraeten; Shibu Thomas; Elahe A Mostaghel; Peter S Nelson; Robert L Vessella; Eva Corey Journal: Clin Cancer Res Date: 2016-12-19 Impact factor: 12.531
Authors: Colm Morrissey; Janice S Lai; Lisha G Brown; Ya-Chun Wang; Martine P Roudier; Ilsa M Coleman; Roman Gulati; Funda Vakar-Lopez; Lawrence D True; Eva Corey; Peter S Nelson; Robert L Vessella Journal: Prostate Date: 2010-03-01 Impact factor: 4.104
Authors: Todd M Morgan; Tiffany E M Pitts; Ted S Gross; Sandra L Poliachik; Robert L Vessella; Eva Corey Journal: Prostate Date: 2008-06-01 Impact factor: 4.104
Authors: Peter S Kirk; Theodore Koreckij; Holly M Nguyen; Lisha G Brown; Linda A Snyder; Robert L Vessella; Eva Corey Journal: Int J Mol Sci Date: 2013-05-21 Impact factor: 5.923